Physician profile
Roy D Ayalon
NPI 1154599546
$9,896.61
in general payments reported to CMS, 2019-2025
10 companies · $6,193 in 2025
The $6,193 reported for 2025 was more than what 94% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.49 · 2020: $108 · 2021: $129 · 2022: $38.68 · 2023: $44.90 · 2024: $3,338 · 2025: $6,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,200 · Food and Beverage: $357 · Travel and Lodging: $18.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,200.00 |
| Food and Beverage | $357.28 |
| Travel and Lodging | $18.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $9,200.00 | 2024-2025 | Bovine Collagen |
| Hologic Sales and Service, LLC | $211.78 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Abbvie INC. | $131.39 | 2020-2022 | |
| Organon LLC | $121.95 | 2024 | |
| Coopersurgical, INC. | $78.62 | 2019-2024 | Paragard T 380a |
| Therapeuticsmd, INC. | $64.60 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $26.01 | 2023 | |
| Exeltis, USA INC. | $21.80 | 2021 | |
| Pfizer INC. | $21.37 | 2022 | |
| Mission Pharmacal Company | $19.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Ayalon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.